PTC Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid, Year One
PTC Therapeutics, Inc. (PTCT) had Lessee, Operating Lease, Liability, to be Paid, Year One of $18.49 million as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-02-19
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $18.49M.
- 2025-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $18.32M.
- 2025-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $16.79M.
- 2025-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $16.69M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2025-12-31 | $18.49M 10-K · filed 2026-02-19 |
| 2025-09-30 | $18.32M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $16.79M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $16.69M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $15.99M 10-K · filed 2025-02-27 |
| 2024-09-30 | $16.23M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $16.18M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $21.00M 10-Q · filed 2024-04-25 |
| 2023-12-31 | $18.35M 10-K · filed 2024-02-29 |
| 2023-09-30 | $18.37M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $18.39M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $18.46M 10-Q · filed 2023-04-27 |
| 2022-12-31 | $15.37M 10-K · filed 2023-02-21 |
| 2022-09-30 | $15.06M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $10.19M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $13.30M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $13.44M 10-K · filed 2022-02-22 |
| 2021-09-30 | $13.23M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $13.31M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $13.24M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $13.72M 10-K · filed 2021-02-25 |
| 2020-09-30 | $13.47M 10-Q · filed 2020-10-29 |
| 2019-12-31 | $6.00M 10-K · filed 2020-03-02 |
| 2018-12-31 | $3.22M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |